Teen boys are going to extreme lengths to be ‘skinny like Timothée Chalamet' — and parents are worried
When Casey's 14-year-old son, Ethan, stopped eating junk food and began obsessively counting calories, he knew something was wrong. Then the boy's waist line began shrinking.
'He is really not eating a lot at meal time,' Casey, who asked to use pseudonyms for himself and his son, told The Post of Ethan, who is 5'8″ and 122 pounds.
The red flags were mild at first. Ethan, an eighth grader at a private school in Manhattan, started turning down ice cream, his favorite dessert despite always having had a sweet tooth.
One night at dinner, Casey noticed his son was taking photos of the food on his plate and uploading them to MyFitnessPal — a weight-loss app — to see how many calories of food he was consuming.
'He's determined to lose weight, but he doesn't have any to lose,' Casey said.
Parents and eating-disorder specialists told The Post how more teenage boys and young men have become hyper-alert about their physique lately — with the muscular and buff look becoming less desirable as waifish stars like Timothée Chalamet and trends like 'mewing' and 'looksmaxing' continue to dominate social media.
'Today's youth are challenging the gender norm more than they have in the past,' said Jason Nagata, an associate professor of pediatrics at the University of California, San Francisco
In other words, dieting is no longer just the domain of girls.
'It used to be boys wanted to bulk up,' Casey told The Post. 'Now, actors like Timothée Chalamet are giving them a whole new look to achieve.'
Just ask 19-year-old Dempsey Bobbit, a Cranford, New Jersey, college freshman who recently won third place in a Chalamet look-alike contest.
'My friends at school that are girls say they want skinny men. It's so the opposite of what you'd expect,' he said. As a result, 'Every guy I know is really critical of what they eat. It's kind of weird. They pay attention to it. They're always trying to get leaner. Broccoli, rice, chicken — chicken is the only protein.'
Bobbit himself is 5′ 9″ and weighs between 120 and 125 pounds, and said he is 'naturally thin' without trying: 'I don't eat a lot, period. I'm into candy, soda. That, and coffee is my diet.'
But, everywhere he goes, he sees other guys his age desperate to get skinny.
'Every time I go to the gym it's like, 'Do I look fat?'' he said of his peers. 'These are normal guys who are self-conscious about how they look.'
One third of adolescent boys in the US are trying to lose weight, according to a 2023 study by the Department of Pediatrics at the University of California, San Francisco found.
Casey believes Ethan and his friends are chasing a romantic ideal.
'Girls the age of my son don't feel threatened by a Timothée Chalamet body, so they kind of communicate this to the boys in their grade,' he said. 'Then [the boys] try to emulate Chalamet's particular brand of masculine acceptability.'
Spencer Delorenzo — a 22-year-old Long Islander who is 5′ 4″ and weighs 98 pounds — told The Post 'women are straying away from the big, muscular guys so men are now interested in losing weight. I have friends who were like, 'Oh I wish I was as skinny as you.''
On TikTok and Reddit, there are plenty of communities and influencers dedicated to how to get Chalamet's cinched waist — he can reportedly fit into size 29 women's jeans — or comedian Matt Rife's chiseled jawline.
An alarming number of teen boys in compression shirts, flexing flat biceps and flaunting tiny waistlines, appear in videos on the 'Skinnerboys' TikTok discover page — which is devoted to 'tips and tricks for skinny boys to look better in style and fitness.'
The hyper obsession with weight is also fueled by the 'looksmaxxing,' in which teen and twenty-something men aim to reshape their jawlines and cheekbones to up their 'sexual market value.'
That has spawned the 'mewing trend' — flattening the tongue to the roof of the mouth to achieve a defined jawline a la Christian Bale's Patrick Bateman character in the movie 'American Psycho.'
TikTok is also full of young men posting their calorie counts and meal plans on the #MyFitnessPal app, which is technically restricted for minors.
It's estimated that 1 in 3 people with an eating disorder are men, and 10 million American boys and men will struggle with the disorder at some point in their lives, according to data from the American Psychological Association.
'I used to be upset if he ate junk food – now I'm buying the junk food. Ice cream, pastries, anything from the bakery,' Casey told The Post. 'My concern is the physical damage it could do by [him] continuing to not eat well.'
At his son's annual physical, Casey said, the doctor told Ethan he needed to gain weight. And Ethan is not the only one in his friend group doing this.
'I started to notice his friends were getting really skinny — seriously getting thin,' Casey told The Post, adding that other parents have told him their young sons are suddenly dieting.
Ironically, Chalamet, 29, has said that, when he was younger he lost roles in the 'Maze Runner' and 'Divergent' film series because 'the feedback was always, 'Oh, you don't have the right body.'
'I had an agent that called me and said, 'You got to put on weight basically,'' the actor told Apple Music's Zane Lowe, adding that he gained 20 pounds for his award-winning role in 'A Complete Unknown.'
But his super slim look is even changing things for young men in Hollywood.
Zander Dueve, 22, who works as an actor and model by day and security guard by night, told The Post casting directors are seeking lanky body types.
'It's definitely a malnourished look,' he said, noting that he is 5′ 11′ and wears a men's size 29 pants. 'It's become a phenomenon — everybody wants that look.
'It's kind of f–ked up that people like it, but it is what it is.'
National Eating Disorder Association (NEDA) website
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Post
an hour ago
- New York Post
Do you have an ‘office chair butt'? Here's what workers who ‘refuse to fall victim' are doing about it
What's droopy, floppy and sagging around the office? No, it's not your crabby boss — it's your flabby butt. Sitting on one's backside for hours on end, slouched in a seat while staring at a computer screen, is flattening once-rounded heinies. 'I refuse to fall victim,' swore Krystina, a NYC-based content creator, warding off the wicked woes of 'office chair butt.' Advertisement 4 Folks online are worried about contracting the dreaded 'office chair butt' while on their jobs. Andrey Popov – Despite its social media-given nickname, the aforementioned curse is a legitimate plague on patooties — more formally known as atrophy of the gluteal muscle group — caused by chronic sitting, according to the Cleveland Clinic. And yes, it's as bad for your booty as it sounds. Advertisement 'A lack of conditioning in your gluteus maximus and surrounding tissue leads to weakness, making it build up fat tissue and appear flatter or saggy,' explained Michael Milicia, an occupational therapist, in a recent report for the clinic. The doc noted that the actual chair a hireling sits in is not to blame for his or her beleaguered bottom. Instead, the true culprit is their lack of movement while on the clock. 'Sitting too long without breaks isn't particularly good for anything,' Milicia said. Advertisement And his butt advisory is right on the nose. Researchers from Beijing, China, recently reconfirmed the cautionary adage, 'sitting is the new smoking,' finding that employees — namely office workers — are at a high risk of experiencing severe neck pain. 4 Investigators have found that sitting for long periods of time can trigger body aches and neck pains. Kittiphan – Kristianne Egbert, a board-certified professional ergonomist, issued a similar warning to The Post, saying, 'holding any one posture for an extended period — whether sitting or standing — can take a toll on your body.' Advertisement 'Static positions cause muscles to tense, slow blood flow and lead to fatigue,' she added. Still, most 9-to-5ers, especially those who've been called to return the office for long-stretch shifts, are forced to park their hind parts in uncomfortable chairs in cramped cubicles for at least five days per week. 4 Experts warn that constant sitting can cause one's buns to become flabby, saggy, flat and squishy. AS/ – The bootylicious online, however, are working their butts to the bone with mid-day exercises, hoping the avoid the ills of office chair atrophy. 'Me every 30 minutes when I find out what office chair butt is,' Haike, a TikTok user, wrote in the closed-captions of a clip that featured her doing knee-lifts at her desk, running up and down a flight of stairs and doing laps around a conference room in her workplace. Loba, an internet influencer from Chicago, stepped away from her workspace to hit a series of squats after catching a shocking glimpse of her flap-jack fanny. And Nikki, a well-endowed diva, lead her team of fellow employees, comprised of both men and women, in executing several repetitions of lunges, squats, leg-lifts and stair climbs, vowing in her vid, 'No office chair butt for us.' Advertisement 4 Squats, leg exercises and butt clenches are all recommended for counteracting the flattening effects of office chair butt, per Cleveland Clinic. T Mdlungu/ – For a Beyonce-like behind, Milica recommends slaying those exercises and more every day, suggesting folks, 'get up and move every 30 to 90 minutes, as your job allows.' Here are a few derrière-improving workouts to help you avoid looking like you've got pancakes in your work pants. Standing while taking a phone call Placing your filing cabinet or other equipment you use during the day a few feet away from your desk Walking to a colleague's office for a face-to-face talk, rather than sending an email Inviting co-workers for a walking meeting Taking the stairs rather than the elevator Choosing a restroom that's a little farther away Switching to a sit-stand desk Try a walking pad under your desk Butt clenches Marching in place Heel lifts Toe lifts Ankle circles Squeezing a ball (or your fists or other prop) between your legs Trying to hold your knees apart while pushing them together when your hands


Medscape
6 hours ago
- Medscape
Perspective Shifts on the Use of MS Meds During Pregnancy
PHOENIX — Two new datasets support the use of potent disease-modifying therapies (DMTs) during pregnancy in women with active multiple sclerosis (MS), reinforcing a growing shift toward treatment when the potential benefit to the mother outweighs the risks. Both studies — one involving the anti-CD20 monoclonal antibody ofatumumab and the other the integrin receptor antagonist natalizumab — are observational, but they provide a foundation for taking a proactive rather than reactive approach to treating pregnant women with active MS, said Riley M. Bove, MD, associate professor of neurology, University of California San Francisco. Bove emphasized that a 'we-don't-know' approach is no longer acceptable when counseling pregnant women with active disease. As first author of the ofatumumab study — presented on May 29 at Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting— she followed up with a lecture the next day, explaining that evidence is now available to guide treatment decisions. Relevant Data While significant knowledge gaps remain about the relative risks of DMTs to fetal development and pregnancy outcomes, it is well established that women with active disease 'will be harmed if we do not help,' Bove said. She and others now believe that the available data, even if observational, are relevant and useful in guiding decisions that affect both maternal and fetal health. The new data on ofatumumab and natalizumab offer a clear example. In an ongoing registry, ofatumumab exposure has been documented in 669 pregnancies. Of these, 221 were reported prior to 2023, allowing for assessment of both short- and long-term outcomes. In most cases (87%), exposure occurred during the first trimester. Adverse outcomes were reported, including spontaneous abortions in 12.6% of cases, preterm births in 9.6%, and minor congenital malformations in two infants (< 1%). However, these rates are 'in line with the background rates observed in the general population,' Bove noted. She emphasized that such data are important when weighing treatment decisions against the known risks of active disease, which can lead to irreversible brain injury in the mother. The natalizumab data, presented as a late-breaking abstract at CMSC on May 30, reflected 16 years of experience at a single center. Tracking began in 2008, when two pregnancies were identified in women already receiving natalizumab. Through 2024, no increased risk for adverse pregnancy outcomes was observed, while natalizumab treatment was associated with meaningful improvements in MS disease control. A total of 58 pregnancies in 43 women have been tracked at the Rocky Mountain MS Clinic in Salt Lake City, according to Katrina Bawden, FNP-C, a nurse practitioner who has been involved since the registry began. Reevaluating Natalizumab She noted that outcomes were analyzed in women who discontinued natalizumab after learning they were pregnant as well as those who continued treatment into the third trimester. Among the 38 pregnancies in which natalizumab was stopped, 13 women experienced clinical relapses, and four others showed new lesions on MRI. In contrast, among the 20 pregnancies where treatment was continued, there were no relapses and no MRI evidence of disease activity. Pregnancy complications were observed, including one fetal malformation and 10 miscarriages, but Bawden noted that these figures — like those in the ofatumumab registry — are consistent with background rates. 'Of the three fetal deaths, all occurred in those who discontinued natalizumab,' she said. She noted that all 10 of the women who miscarried had healthy term full term deliveries in a subsequent pregnancy while remaining on natalizumab. Compared to the start of the tracking period, Bawden said the data have prompted clinicians at her clinic to reevaluate the benefit-risk balance of using natalizumab during pregnancy. 'Women at the Rocky Mountain MS Clinic who become pregnant while treated with natalizumab, using shared decision-making, are now given the option of continuing natalizumab every 8 weeks throughout pregnancy with the last dose scheduled at 34 weeks' gestation,' Bawden said. 'Illogical Guidance' Caring for pregnant women with MS is a complex challenge, given the incomplete information available. However, Bove — co-author of a 2024 paper on practical considerations for weighing the risks and benefits of DMT use during pregnancy — said that strictly following drug labeling is not helpful in guiding clinical decisions. She noted that current recommendations are inconsistent across drug classes, vary between the FDA and the European Medicines Agency, and often fail to reflect the latest science — resulting in guidance that is ultimately 'illogical.' Moreover, labeling continues to evolve, and pregnancy-related use of DMTs remains a dynamic area, with new data — such as the recent studies presented at CMSC — shaping clinical strategies. Bove emphasized that it is the clinician's responsibility to stay informed as the evidence develops, in order to support shared decision-making. This includes staying up to date on when to treat active disease during pregnancy, when to restart therapy if it was paused, and how to weigh the benefit-risk profile of DMTs for women who choose to breastfeed. When making MS treatment decisions during pregnancy, the adage 'first, do no harm' has traditionally focused on fetal risk. But Bove pointed out that withholding treatment may, in many cases, pose greater harm to the mother, underscoring the need for a balanced discussion that considers risks to both mother and fetus.


Medscape
6 hours ago
- Medscape
Evidence Shifts Perspective on MS Drug Use in Pregnancy
PHOENIX — Two new datasets support the use of potent disease-modifying therapies (DMTs) during pregnancy in women with active multiple sclerosis (MS), reinforcing a growing shift toward treatment when the potential benefit to the mother outweighs the risks. Both studies — one involving the anti-CD20 monoclonal antibody ofatumumab and the other the integrin receptor antagonist natalizumab — are observational, but they provide a foundation for taking a proactive rather than reactive approach to treating pregnant women with active MS, said Riley M. Bove, MD, associate professor of neurology, University of California San Francisco. Bove emphasized that a 'we-don't-know' approach is no longer acceptable when counseling pregnant women with active disease. As first author of the ofatumumab study — presented on May 29 at Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting— she followed up with a lecture the next day, explaining that evidence is now available to guide treatment decisions. Relevant Data While significant knowledge gaps remain about the relative risks of DMTs to fetal development and pregnancy outcomes, it is well established that women with active disease 'will be harmed if we do not help,' Bove said. She and others now believe that the available data, even if observational, are relevant and useful in guiding decisions that affect both maternal and fetal health. The new data on ofatumumab and natalizumab offer a clear example. In an ongoing registry, ofatumumab exposure has been documented in 669 pregnancies. Of these, 221 were reported prior to 2023, allowing for assessment of both short- and long-term outcomes. In most cases (87%), exposure occurred during the first trimester. Adverse outcomes were reported, including spontaneous abortions in 12.6% of cases, preterm births in 9.6%, and minor congenital malformations in two infants (< 1%). However, these rates are 'in line with the background rates observed in the general population,' Bove noted. She emphasized that such data are important when weighing treatment decisions against the known risks of active disease, which can lead to irreversible brain injury in the mother. The natalizumab data, presented as a late-breaking abstract at CMSC on May 30, reflected 16 years of experience at a single center. Tracking began in 2008, when two pregnancies were identified in women already receiving natalizumab. Through 2024, no increased risk for adverse pregnancy outcomes was observed, while natalizumab treatment was associated with meaningful improvements in MS disease control. A total of 58 pregnancies in 43 women have been tracked at the Rocky Mountain MS Clinic in Salt Lake City, according to Katrina Bawden, FNP-C, a nurse practitioner who has been involved since the registry began. Reevaluating Natalizumab She noted that outcomes were analyzed in women who discontinued natalizumab after learning they were pregnant as well as those who continued treatment into the third trimester. Among the 38 pregnancies in which natalizumab was stopped, 13 women experienced clinical relapses, and four others showed new lesions on MRI. In contrast, among the 20 pregnancies where treatment was continued, there were no relapses and no MRI evidence of disease activity. Pregnancy complications were observed, including one fetal malformation and 10 miscarriages, but Bawden noted that these figures — like those in the ofatumumab registry — are consistent with background rates. 'Of the three fetal deaths, all occurred in those who discontinued natalizumab,' she said. She noted that all 10 of the women who miscarried had healthy term full term deliveries in a subsequent pregnancy while remaining on natalizumab. Compared to the start of the tracking period, Bawden said the data have prompted clinicians at her clinic to reevaluate the benefit-risk balance of using natalizumab during pregnancy. 'Women at the Rocky Mountain MS Clinic who become pregnant while treated with natalizumab, using shared decision-making, are now given the option of continuing natalizumab every 8 weeks throughout pregnancy with the last dose scheduled at 34 weeks' gestation,' Bawden said. 'Illogical Guidance' Caring for pregnant women with MS is a complex challenge, given the incomplete information available. However, Bove — co-author of a 2024 paper on practical considerations for weighing the risks and benefits of DMT use during pregnancy — said that strictly following drug labeling is not helpful in guiding clinical decisions. She noted that current recommendations are inconsistent across drug classes, vary between the FDA and the European Medicines Agency, and often fail to reflect the latest science — resulting in guidance that is ultimately 'illogical.' Moreover, labeling continues to evolve, and pregnancy-related use of DMTs remains a dynamic area, with new data — such as the recent studies presented at CMSC — shaping clinical strategies. Bove emphasized that it is the clinician's responsibility to stay informed as the evidence develops, in order to support shared decision-making. This includes staying up to date on when to treat active disease during pregnancy, when to restart therapy if it was paused, and how to weigh the benefit-risk profile of DMTs for women who choose to breastfeed. When making MS treatment decisions during pregnancy, the adage 'first, do no harm' has traditionally focused on fetal risk. But Bove pointed out that withholding treatment may, in many cases, pose greater harm to the mother, underscoring the need for a balanced discussion that considers risks to both mother and fetus.